Biotechnology Company Deals With Other Biotechnology Companies: Dec. 1, 2012 - Feb. 21, 2013

(BioWorld Insight Via Acquire Media NewsEdge) Total Value in 2013: $5,016.9M* Number of Deals in 2013: 37 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Amarantus BioScience Inc. (Sunnyvale, Calif.) Power3 Medical Products Inc.(Houston) $0.04 Deal to buy all of the intellectual property assets from Power3, giving Amarantus the ability to acquire IP for the diagnosis of multiple neurodegenerative diseases and oncology Amarantus is paying $40,000, and the deal includes five patents and 20 pending patent applications 12/27/12 biOasis Technologies Inc. (Vancouver, British Columbia) UCB SA (Brussels, Belgium) ND Deal to evaluate the application of biOasis' technology for drug delivery to the brain biOasis will carry out studies of the technology as it relates to UCB's central nervous system compounds 12/4/12 Biogen Idec Inc. (Weston, Mass.) Isis Pharmaceuticals Inc. (Carlsbad, Calif.) $200 Partnership to discover and develop antisense drugs for several undisclosed targets in the area of neurological and neuromuscular disorders Biogen Idec will pay Isis $30M up front to discover a lead candidate for each of three targets, and Isis will be eligible for milestone payments; Biogen Idec also has an option to license a drug from each of those three programs through completion of Phase II trials; payments to Isis could total $200 million, including license fees and regulatory milestones per program, plus additional double-digit royalties 12/11/12 BrainStorm Cell Therapeutics Inc. (New York) Octane Biotech (Kingston, Ontario) ND Deal to jointly develop a bioreactor for production of its NurOwn stem cell therapy candidate The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, and the project is supported by a grant from the Canada-Israel Industrial Research and Development Foundation 12/18/12 Galena Biopharma Inc. (Lake Oswego, Ore.) Leica Biosystems (Newcastle-Upon-Tyne, UK) ND Partnership to develop a companion diagnostic for Galena's NeuVax (nelipepimut-S or E75) breast cancer therapeutic Leica's Bond Oracle HER2 IHC System companion diagnostic will be used to support the selection of the appropriate patients for the NeuVax Phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment) study 12/7/12 Genovax srl(Colleretto Giacosa, Italy) Mediolanum Farmaceutici SpA (Milan, Italy) ND Mediolanum acquired rights to GX301, a cancer vaccine, from Genovax Mediolanum will take over further development and commercialization of the drug, with support from Genovax, in exchange for up-front and milestone payments, plus royalties.

12/4/12 H3 Biomedicine Inc.(Cambridge, Mass.) Sage Bionetworks(Seattle) ND Partnership to develop software platforms for cancer genomics research Sage will use its predictive modeling technology with H3's data to find associations between genomic alterations and pharmacologic drug responses; the two companies will also freely share the data and tools from the project with other organizations involved in cancer research 12/20/12 ImmunoGen Inc. (Waltham, Mass.) Amgen Inc.(Thousand Oaks, Calif.) $70 Licensing agreement for the exclusive right to use its maytansinoid targeted antibody payload technology to develop cancer therapeutics for a third, undisclosed target Amgen licensed rights to two other cancer targets in 2009 and has two compounds in clinical testing under those licenses; for each license, ImmunoGen received $1M up front and is entitled to milestone payments potentially totaling $34M, plus royalties on product sales 12/20/12 MedImmune (Gaithersburg, Md.) Progenics Pharmaceuticals Inc. (Tarryton, N.Y.) ND Deal to license a preclinical program for Clostridium difficile MedImmune will investigate efficacy and safety of a set of investigational monoclonal antibodies targeting toxins that are significant to the disease 12/18/12 MorphoSys AG (Martinsried, Germany) Bio-Rad Laboratories Inc.(Hercules, Calif.) $69.7 Sale of MorphoSys' Abd Serotec unit focused on research and diagnostic antibodies MorphoSys will receive €53M ($69.7M) in cash for the unit, and the transaction is expected to close in January 2013, with 130 employees transferring over to Bio-Rad 12/18/12 NovaDel Pharma Inc. (Bridgewater, N.J.) Suda Ltd. (Australia) ND NovaDel signed a preliminary agreement to sell its NovaMist technology to Suda The proposed transaction includes the sale of NovaDel's patents and trademarks relating to its NovaMist technology but does not include the NitroMist or ZolpiMist intellectual property or licenses 12/28/12 Open Monoclonal Technology Inc. (Palo Alto, Calif.) Crystal Bioscience Inc. (Emeryville, Calif.) ND Strategic alliance allowing OMT to use Crystal's antibody screening technology for its Gel-Encapsulated Microenvironment antibody screening platform The technology is designed to identify all antibodies of a specific target across large populations of lymphocytes 12/5/12 QLT Inc. (Vancouver, British Columbia) Mati Therapeutics Inc.

$0.503 Agreement to grant Mati a 90-day option to acquire QLT's punctal plug drug delivery system for C$0.5M (US$0.503M) If Mati exercises that option, the two companies will make an asset purchase agreement entitling QLT to C$0.75M, milestone payments and low single-digit royalties on worldwide net sales of products developed using the technology 12/27/12 Radius Health Inc. (Cambridge, Mass.) 3M Drug Delivery Systems (St. Paul, Minn.) ND Partnership for development and commercialization of BA058-transdermal (TD), a synthetic peptide analogue of human parathyroid hormone-related protein (hPTHrP) The agreement updates the general development agreement announced in May 2011 by the two companies for BA058-TD 12/26/12 Single Cell Technology Inc. (San Jose, Calif.) Open Monoclonal Technology Inc. (Palo Alto, Calif.) ND Collaboration allowing OMT to use its OmniRat transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT, and SCT will use its platform to massively screen plasma cells, measure the kinetics of secreted antibodies and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing SCT will advance and partner the program and share the economics with OMT, depending on the stage of development. SCT also will have an option to develop and commercialize selected products resulting from the research 12/4/12 Sutro Biopharma Inc. (South San Francisco) Celgene Corp.(Summit, N.J.) $500 $500M deal includes two undisclosed targets against which antibody conjugates and bispecific antibodies will be deployed, plus the manufacturing of a Celgene-owned antibody The deal brings a "substantial" up-front amount and includes milestone payments for Sutro as the companies will design and develop antibody-drug conjugates (ADCs) and bispecific antibodies for two targets, using Sutro's cell-free protein synthesis technology 12/19/12 uniQure BV (Amsterdam, the Netherlands) Benitec Biopharma Ltd.(Melbourne, Australia) ND Nonexclusive cross-licensing deal, gaining access to Benitec's DNA-directed RNA interference (ddRNAi) technology in Huntington's disease uniQure granted Benitec nonexclusive access to its AAV5 delivery technology for the development of a ddRNAi therapy for hepatitis B 12/6/12 Ventria Bioscience Inc.(Fort Collins, Colo.) Meristem Therapeutics(Paris) ND Agreement under which Ventria will acquire portions of the intellectual property portfolio relating to recombinant lactoferrin developed by Meristem Ventria gains exclusive, royalty-free ownership rights for specific patents, including those related to recombinant human lactoferrin, in exchange for a one-time payment 12/4/12 YM BioSciences Inc. (Mississauga, Ontario) InnoKeys PTE Ltd. (Singapore) $2 YM sold assets related to nimotuzumab to InnoKeys InnoKeys paid $2M immediately plus undisclosed additional consideration 12/5/12 JANUARY 4-Antibody AG (Basel, Switzerland) Recepta Biopharma SA (Sao Paulo, Brazil) ND Multitarget research and development collaboration Deal represents an expansion of a partnership the Ludwig Institute and 4-Antibody initiated a year ago 1/30/13 Afraxis Inc.(San Diego) Genentech (unit of the Roche Group; Basel, Switzerland) $187.5 Licensing deal giving Genentech exclusive, worldwide rights to develop and commercialize Afraxis' compounds against a novel undisclosed target Deal includes $10M up front, plus milestones that make it potentially worth $187.5M 1/29/13 Algeta ASA (Oslo, Norway) Immunomedics Inc. (Morris Plains, N.J.) ND Agreement that requires Immunomedics to provide clinical-grade antibody, and for Algeta to fund all preclinical and clinical development through the end of Phase I for a therapeutic combining thorium-227 alpha-pharmaceutical agent with an anti-CD22 monoclonal antibody (epratuzumab) The companies may negotiate for a license; Algeta will pay a signature fee, milestone payments for antibody delivery and payments for cGMP antibody manufacturing 1/29/13 Apeiron Biologics AG (Vienna, Austria) Paladin Labs Inc. (Montreal) ND Out-licensing agreement for APN311 Paladin gains the exclusive rights to market and sell APN311 in Canada and sub-Saharan Africa 1/22/13 BioTime Inc. (Alameda, Calif.) and a newly created subsidiary BioTime Acquisition Corp.

Geron Corp. (Menlo Park, Calif.) $5 Agreement to acquire Geron's human embryonic stem cell program BioTime will pay $5M in cash, plus 8.9M BioTime common shares, five-year warrants for 8M common shares at $5 per share, rights to clinical grade hESC lines, a sublicense for certain stem cell patents and minority stakes in BioTime subsidiaries; BAC will pay royalties to Geron; a private investor will make a $5M equity investment in BAC and a $5M investment in BioTime as part of the deal 1/8/13 BIND Biosciences Inc. (Cambridge, Mass.) Amgen Inc. (Thousand Oaks, Calif.) $180.5 Deal to collaborate on development of a nanotechnology-based therapeutic for solid tumors The deal is worth up to $180.5M, with an allowance for additional payments for other indications, as well as tiered royalties on future sales; up-front fees and development milestones are $46.5M, with $134M in potential regulatory and sales milestones for the first therapeutic indication 1/9/13 Domain Therapeutics SA (Strasbourg, France) Prexton Therapeutics (Geneva) ND Exclusive option agreement to license and develop metabotropic glutamate receptor 4 positive allosteric modulator drugs targeting Parkinson's disease Terms were not disclosed 1/23/13 Emergent BioSolutions Inc. (Rockville, Md.) VaxInnate Corp. (Cranbury, N.J.) ND License agreement for the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the U.S.

Terms were not disclosed 1/2/13 Epizyme Inc. (Cambridge, Mass.) Eisai Co. Ltd. (Tokyo) and Roche AG (Basel, Switzerland) ND Collaboration to develop an in vitro polymerase chain reaction(PCR)-based companion diagnostic test The test will identify lymphoma patients with nonwild type EZH2, including the Y641 mutation 1/8/13 Evotec AG (Hamburg, Germany) Apeiron Biologics AG (Vienna, Austria) ND Research collaboration to develop immunomodulatory lead compounds for cancer Apeiron will contribute in vitro and in vivo pharmacology expertise, while Evotec will be responsible for chemistry and chemical proteomics 1/3/13 Heptares Therapeutics Ltd. (Garden City, UK) Cubist Pharmaceuticals Inc. (Lexington, Mass.) $9.5 Partnership on Heptares' G protein-coupled receptor technology centered on one, or possibly two, targets Heptares will receive $5.5M up front and about $4M in research funding for the first target, with milestones and royalties to follow 1/8/13 Inviragen Inc. (Fort Collins, Colo.) Vabiotech (Hanoi, Vietnam) ND Licensing agreement giving Vabiotech rights to Japanese encephalitis technology to produce a cell-derived vaccine Vabiotech may exclusively develop and commercialize a JE vaccine based on that technology in Vietnam, Cambodia and Myanmar; Inviragen will receive development-based milestone payments 1/4/13 MacroGenics Inc. (Rockville, Md.) Gilead Sciences Inc. (Foster City, Calif.) $1B Deal to deploy MacroGenics' DualAffinity ReTargeting technology for drugs directed at up to four targets MacroGenics will collect as much as $30M in license fees, and possibly $85M more in preclinical milestone payments, plus clinical, regulatory and commercialization milestones raising the deal's value to $1B; Gilead owns exclusive worldwide rights to three programs, whereas MacroGenics retains rights outside North America, Europe, Australia and New Zealand for the fourth 1/8/13 Medivir AB (Stockholm, Sweden) Janssen Pharmaceuticals Inc. (Johnson & Johnson unit; New Brunswick, N.J.) and Idenix Pharmaceuticals Inc. (Cambridge, Mass.) ND Nonexclusive collaboration for the clinical development of an all-oral direct-acting antiviral hepatitis C combination therapy The collaboration will evaluate combinations including simeprevir, TMC647055 and IDX719 1/29/13 Onconova Therapeutics Inc. (Newtown, Pa.) GVK BIO (Hyderabad, India) ND Partnership to develop products for two Onconova discovery targets through clinical stage As the programs advance, GVK BIO will gain an increasing share, up to a 50-50 split 1/10/13 Pepscan Therapeutics BV (Lelystad, the Netherlands) Undisclosed U.S.-based antibody discovery company ND Multitarget research deal under which Pepscan will use its CLIPS platform and other protein mimicry technologies to help discover new antibodies Pepscan will get R&D funding and could receive payments for research and clinical milestones, plus royalties 1/8/13 ScinoPharm Taiwan Ltd. (Tainan, Taiwan) Foresee Pharmaceuticals Inc. (Newark, Del.) $3.6 Investment agreement to form a joint venture to develop a series of peptide injectable drugs ScinoPharm agreed to invest $3.6M for a minority ownership in the new company 1/31/13 Velocity Pharmaceutical Development LLC (South San Francisco) EuMederis Pharmaceuticals Inc. (San Diego) ND Licensing agreement to pursue a drug development program using EuMederis' EuPort technology Research and further development will be funded and carried out through a special purpose development company, Spitfire Pharma Inc.

1/16/13 Verastem Inc. (Cambridge, Mass.) Laboratory Corp. of America Holdings (Burlington, N.C.) ND Partnership to validate biomarkers for VS-6063 as a companion diagnostic in ovarian cancer and mesothelioma The deal includes a pivotal study scheduled for later in 2013 1/10/13 FEBRUARY Aduro BioTech Inc. (Berkeley, Calif.) BioSante Pharmaceuticals Inc. (Lincolnshire, Ill.) $1 Aduro acquired all the GVAX assets from BioSante including intellectual property and cell lines The acquisition covers all uses and includes additional vaccines for multiple myeloma and breast and colon cancers and assumes rights to the existing agreement for GVAX Melanoma; Aduro paid BioSante $1M up front and has committed to additional milestone and royalty payments 1/5/13 Argenta Ltd. (Harlow, UK) Antabio (Lebege, France) ND Deal to provide medicinal chemistry, computer-aided drug design and ADME/PK services to assist Antabio in the identification of antibacterial agents The collaboration is funded by a Wellcome Trust Seeding Drug Discovery award 2/8/13 Biogen Idec Inc. (Weston, Mass.) Elan Corp. plc (Dublin, Ireland) $3.25B Biogen is buying all rights from Elan to the multiple sclerosis therapy Tysabri Biogen will pay $3.25B for the rights; Elan is entitled to 12% of Tysabri sales for the first 12 months, and then 18% of sales up to $2B and 25% of sales over that amount 2/7/13 Caliber Biotherapeutics LLC (Bryan, Texas) iBio Inc. (Newark, Del.) ND License and collaboration deal for development and production of recombinant, plant-based biopharmaceuticals based on iBio's technology platform and using Caliber's manufacturing capabilities iBio will receive license and milestone fees for development of product targets selected by Caliber, which will fund clinical development and commercialization of products, paying iBio royalties on product sales 2/20/13 Dyax Corp. (Burlington, Mass.) Novellus Biopharma AG (Bogota, Colombia) ND Partnership for the development and commercialization of hereditary angioedema drug Kalbitor in select regions in Latin America Dyax will get an up-front payment and will be eligible for future sales milestones and royalties 2/1/13 Genentech Inc. (South San Francisco) RQx Pharmaceuticals Inc. (San Diego) $111 Agreement to develop drugs for an undisclosed disease target in the area of antibiotic-resistant bacteria Deal includes an up-front fee, milestone payments and potential royalties; deal is worth $111M 2/12/13 Inspiration Biopharma-ceuticals Inc.(Cambridge, Mass.) Cangene Corp. (Winnipeg, Manitoba) $55.9 Inspiration sold its hemophilia B product, IB1001 to Cangene Cangene gains worldwide rights, as well as rights to two preclinical products, IB1007 and IB1008, in exchange for an up-front payment of $5.9M, sales milestones of up to $50M and royalties tiered up to a double-digit percentage of global net sales 2/7/13 MorphoSys AG (Martinsried, Germany) Heptares Therapeutics Ltd. (Welwyn Garden City, UK) ND Partnership to discover antibody therapies for G protein-coupled receptors Heptares will generate stabilized receptors for GPCR disease targets chosen by MorphoSys, which may sublicense the targets to third parties, and is eligible for license fees, milestones and royalties on any Ylanthia antibody developed 2/14/13 Pergamum AB (Stockholm, Sweden) Cadila Pharmaceuticals Ltd. (Ahmedabad, India) ND Collaboration to develop a treatment of infections using a targeting mechanism distinguished from classical antibiotics The firms will work together on preclinical and clinical development for the therapeutic peptide, developed by Permagum, with Cadila taking on all costs related to development up to Phase II 2/11/13 Phylogica Ltd. (Perth, Australia) Bio-Link Australia Pty. Ltd. (Sydney, Australia) ND Agreement to commercialize a family of anti-inflammatory Phylomer peptides for pharmaceutical use BioLink will work with Phylogica to monetize those assets through out-licensing or disposal of the Phylomer peptides to a pharma or biotech company 2/6/13 Santen Inc. (Emeryville, Calif.; subsidiary of Santen Pharmaceuticals Co. Ltd.) Clearside Biomedical Inc. (Alpharetta, Ga.) $7.9 Research collaboration for posterior ocular diseases Santen will join other investors to fund an additional $7.9M for continued development of CSL1001 into pivotal testing and to further Clearside's pipeline in ocular choroidal neovascularization and inflammatory diseases of the posterior segment 2/1/13 Stem Cell Therapeutics Corp. (Toronto) ReNeu Inc. (Calgary, Alberta) and NexGen Medical Systems Inc. (Melbourne, Fla.) ND Joint venture agreement under which SCT and NexGen will license their respective technologies to ReNeu In exchange for worldwide, royalty-free licenses to NexGen's EViTAR line of intracranial delivery systems and SCT's NTx-265, -428 and -488 covering the use of drugs for the regeneration of endogenous neural stem cells, SCT will own 50% of the joint venture 2/21/13 The Medicines Co. (Parsippany, N.J.) Alnylam Pharmaceuticals Inc. (Cambridge, Mass.) $205 Deal for Alnylam's RNA interference approach to blocking proprotein convertase subtilisin/kexin type 9 Medicines is paying $25M up front, plus as much as $180M in milestones and double-digit royalties; Alnylam will develop the program through preclinical and early clinical trials, and Medicines will take over from Phase II onward, as well as commercialization 2/5/13 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found.

* The total value represents the amount of disclosed money involving collaborations between biotechnology companies, including manufacturing, marketing and distribution agreements detailed in the following chart.

(c) 2013 AHC Media LLC. All Rights Reserved.

[ Back To Technology News's Homepage ]